recombinant intravenous immunoglobulin

Recombinant intravenous immunoglobulin (rIVIG) is a recombinant polyclonal antibody therapy being developed by GigaGen (a subsidiary of Grifols) for the treatment of primary immunodeficiencies and other conditions requiring IVIG or pathogen-specific antibodies. Unlike traditional plasma-derived IVIG, which is limited by donor supply and batch-to-batch variability, rIVIG is produced in mammalian cell lines using a proprietary single-cell technology that captures and recreates the complete immune repertoire of healthy donors. This specific product candidate combines a broad antibody repertoire mirroring common-disease immunity with high-titer recombinant antibodies against specific pathogens, potentially offering significantly higher potency and a more consistent safety profile than conventional plasma-based products.

Other names

recombinant IVIGrecombinant polyclonal antibodyIVIG + High Titer Recombinant Anti-Pathogen Hyperimmunehigh-titer recombinant anti-pathogen hyperimmune